AZD3293 - Articles and news items

Alzheimer's disease definition

AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease

Industry news / 23 August 2016 / AstraZeneca

AstraZeneca and Eli Lilly and Company have received US FDA Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in Phase III clinical trial.

Phase II/III trial of AZD3293 in early Alzheimer’s disease to continue

Industry news / 8 April 2016 / Victoria White

AstraZeneca and Lilly have announced that AMARANTH, a Phase II/III study of AZD3293 will continue into Phase III of the Phase II/III seamless trial…


Pharma Partnerships Vital in Stagnant Alzheimer’s Disease Treatment Market, says GlobalData Analyst

Industry news / 23 September 2014 / GlobalData

Eli Lilly’s recent partnership with AstraZeneca to develop oral beta-secretase cleaving enzyme (BACE) inhibitor AZD3293 for Alzheimer’s Disease (AD) is a positive step forward for this challenging treatment market, says an analyst with research and consulting firm GlobalData…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...